Uni Eropa - Malta - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - trajenta huwa indikat fit-trattament tad-dijabete tat-tip 2 mellitus biex itejbu l-kontroll gliċemiku fl-adulti:kif monotherapyin pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba l-intolleranza, jew kontra-indikat minħabba l-indeboliment tal-kliewi. bħala kombinazzjoni therapyin flimkien ma 'metformin meta d-dieta u l-eżerċizzju flimkien ma' metformin waħdu ma jipprovdux kontroll gliċemiku adegwat. f'kombinazzjoni ma ' sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat. flimkien ma 'l-insulina bi jew mingħajr metformin, meta dan ir-reġim waħdu, ma' dieta u eżerċizzju, ma jipprovdux kontroll gliċemiku adegwat.

Uni Eropa - Malta - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Uni Eropa - Malta - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5.

Uni Eropa - Malta - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vokanamet huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku:f'pazjenti li mhumiex kontrollati sew fuq xieraq bl-felħu dożi ta' metformin alonein pazjenti fuq xieraq bl-felħu dożi ta 'metformin flimkien ma' oħrajn li jbaxxu glucose-prodotti mediċinali inkluża l-insulina, meta dawn ma jipprovdux kontroll gliċemiku adegwat. fil-pazjenti li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta canagliflozin u metformin bħala separati tabletsfor-riżultati tal-istudju fir-rigward tal-kombinazzjoni ta ' terapiji, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati, ara sezzjonijiet 4. 4, 4. 5 u 5.

Uni Eropa - Malta - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Uni Eropa - Malta - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid - diabetes mellitus, tip 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku:bħala monoterapija f'pazjenti li għalihom l-użu ta' metformin huwa kkunsidrat xieraq minħabba 'intolleranza jew ta' kontra-indikazzjonijiet. barra minn hekk oħra prodotti mediċinali għall-kura tad-dijabete.

Uni Eropa - Malta - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Uni Eropa - Malta - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Uni Eropa - Malta - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - għall-pazjenti b'dijabete tat-tip 2 mellitus:efficib huwa indikat bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku għal pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta 'metformin waħdu jew għal dawk li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta' sitagliptin u metformin. efficib huwa indikat f'kombinazzjoni ma ' sulphonylurea (i. terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. efficib huwa indikat bħala terapija ta 'kumbinazzjoni tripla ma' ppar-agonist (i. thiazolidinedione) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta ' metformin u agonista ppar. efficib huwa indikat ukoll bħala add-on għall-insulina (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti meta stabbli fid-dożaġġ ta' l-insulina u metformin waħdu ma jipprovdux kontroll gliċemiku adegwat.

Uni Eropa - Malta - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - glyxambi, taħlita fissa tad-doża ta empagliflozin u linagliptin, huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta metformin u/jew mediċina tat-tip sulphonylurea (su) u waħda mill-monokomponenti tal-glyxambi ma jipprovdux kontroll gliċemiku adegwat;meta diġà qegħdin jiġu ttrattati bil-kombinazzjoni ħielsa ta empagliflozin u linagliptin.